These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

735 related items for PubMed ID: 12671453

  • 41. CARESS: the Canadian registry of palivizumab.
    Mitchell I, Paes BA, Li A, Lanctôt KL, CARESS investigators.
    Pediatr Infect Dis J; 2011 Aug; 30(8):651-5. PubMed ID: 21343842
    [Abstract] [Full Text] [Related]

  • 42. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD.
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [Abstract] [Full Text] [Related]

  • 43. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
    Singleton RJ, Bruden D, Bulkow LR, Varney G, Butler JC.
    Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
    [Abstract] [Full Text] [Related]

  • 44. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.
    Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O.
    Pediatr Infect Dis J; 2007 Dec; 26(12):1089-93. PubMed ID: 18043443
    [Abstract] [Full Text] [Related]

  • 45. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
    Fitzgerald DA.
    Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
    Marchetti A, Lau H, Magar R, Wang L, Devercelli G.
    Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
    [Abstract] [Full Text] [Related]

  • 49. [Treatment of infants with RSV infection: a retrospective analysis of the season 1998/99].
    Schauer U, Rieger CH.
    Klin Padiatr; 2002 Apr; 214(1):37-40. PubMed ID: 11823952
    [Abstract] [Full Text] [Related]

  • 50. Palivizumab use in very premature infants in the neonatal intensive care unit.
    Wu SY, Bonaparte J, Pyati S.
    Pediatrics; 2004 Nov; 114(5):e554-6. PubMed ID: 15520088
    [Abstract] [Full Text] [Related]

  • 51. [Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections].
    Scholz H.
    Z Geburtshilfe Neonatol; 2000 Nov; 204(3):120-2. PubMed ID: 10909169
    [Abstract] [Full Text] [Related]

  • 52. [Respiratory syncytial virus prophylaxis among preterm infants--four seasons' experience].
    Klimek M, Kwinta P, Kruczek P, Pietrzyk JJ.
    Przegl Lek; 2009 Nov; 66(1-2):34-8. PubMed ID: 19485253
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody.
    DeVincenzo JP, Aitken J, Harrison L.
    J Pediatr; 2003 Jul; 143(1):123-6. PubMed ID: 12915838
    [Abstract] [Full Text] [Related]

  • 55. Respiratory syncytial virus disease: update on treatment and prevention.
    Krilov LR.
    Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875
    [Abstract] [Full Text] [Related]

  • 56. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
    Groothuis JR, Hoopes JM, Hemming VG.
    Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
    [Abstract] [Full Text] [Related]

  • 57. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit.
    Abadesso C, Almeida HI, Virella D, Carreiro MH, Machado MC.
    J Hosp Infect; 2004 Sep; 58(1):38-41. PubMed ID: 15350712
    [Abstract] [Full Text] [Related]

  • 58. Infection by the respiratory syncytial virus in infants and young children at high risk.
    Bonnet D, Schmaltz AA, Feltes TF.
    Cardiol Young; 2005 Jun; 15(3):256-65. PubMed ID: 15865827
    [Abstract] [Full Text] [Related]

  • 59. Late preterm infants and risk for RSV.
    Coffman S.
    MCN Am J Matern Child Nurs; 2009 Jun; 34(6):378-84; quiz 385-6. PubMed ID: 19901700
    [Abstract] [Full Text] [Related]

  • 60. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH.
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.